Skip to main content
Clinical Trials/CTRI/2021/04/032587
CTRI/2021/04/032587
Completed
未知

Evaluation of Dermatological safety of Test products by primary irritation patch test on healthy human volunteers of varied skin types

Freedom Fragrances0 sites24 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Freedom Fragrances
Enrollment
24
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
April 15, 2021
Last Updated
3 years ago
Study Type
Interventional

Investigators

Sponsor
Freedom Fragrances

Eligibility Criteria

Inclusion Criteria

  • 1\. Healthy male and female subjects in the age group of 18\-45 years (both age inclusive)
  • 2\. Subjects with Fitzpatrick skin type III to V
  • 3\. Subjects willing to give a voluntary written informed consent
  • 4\. Subjects willing to maintain the test patches in designated positions for 24 Hours
  • 5\. Subjects having not participated in a similar investigation in the past two weeks
  • 6\. Subjects willing to come for regular follow up visits
  • 7\. Subjects ready to follow instructions during the study period
  • 8\. Subjects without any open wounds, cuts, abrasions, irritation symptoms

Exclusion Criteria

  • 1\. Subjects with Infection/ allergy/ irritation symptoms on the upper back area identified for patch application
  • 2\. Subjects with any kind of skin allergy, antecedents or atopy or cutaneous disease which may influence the study results
  • 3\. Subject is Pregnant or Lactating
  • 4\. Athletes and subjects with a history of excessive sweating
  • 5\. Subjects on an oral corticosteroid, or using any topical or systemic medicine which might interfere with the study results
  • 6\. Subjects participating in any other cosmetic or therapeutic trial
  • 7\. Subjects with any history of underlying uncontrolled medical illness including diabetes, liver disease, or history of alcoholism, HIV, or any other serious medical illness

Outcomes

Primary Outcomes

Not specified

Similar Trials